Algert Global’s UroGen Pharma URGN Stock Holding History

Algert Global’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	32,350 +13,360	+70%	+$362K	0.01%	948
2026 Q1	$341K	Sell	18,990 -46,945	-71%	-$941K	0.01%	1011
2025 Q4	$1.54M	Buy	+65,935	New	+$1.43M	0.02%	769
2022 Q3	–	Sell	-10,350	Closed	-$85K	–	1350
2022 Q2	$85K	Sell	10,350 -190	-2%	-$1.3K	0.01%	1131
2022 Q1	$92K	Buy	+10,540	New	+$82.2K	0.01%	1110
2021 Q2	–	Sell	-11,630	Closed	-$227K	–	532
2021 Q1	$227K	Buy	+11,630	New	+$247K	0.07%	359
2020 Q3	–	Sell	-10,880	Closed	-$284K	–	488
2020 Q2	$284K	Buy	+10,880	New	+$266K	0.1%	279

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Algert Global's URGN Position: Q2 2026 in Review

Algert Global increased its UroGen Pharma (URGN) stake by 70% in Q2 2026, buying an estimated $362K and bringing the position to 32,350 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #948.

Algert Global first reported a position in URGN in Q2 2020 and has held it in 7 quarters since. The position peaked at $1.54M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Algert Global held 32,350 shares of UroGen Pharma worth $1.19M as of Q2 2026.
Algert Global bought 13,360 UroGen Pharma shares in Q2 2026, an estimated $362K.
UroGen Pharma made up 0.01% of Algert Global's portfolio in Q2 2026, its #948 holding.
Algert Global first reported a position in UroGen Pharma in Q2 2020 and has held it in 7 quarters since.
Algert Global's UroGen Pharma position peaked at $1.54M in Q4 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.